Regeneration's xenograft screw:
This article was originally published in Clinica
Executive Summary
Regeneration Technologies', Sterling, interference screw for use in an arthroscopic or open ACL and/or PCL reconstruction. It has a long-term absorption rate, which ensures secure graft fixation throughout the healing process, and a pullout strength that is comparable to metal interference screws, says the Alachua, Florida firm. The implant is treated with the company's patented BioCleanse tissue sterilisation process, which is designed to eliminate viruses, bacteria, fungi and spores from tissue without impacting its structural or biomechanical integrity. The screw is expected to become available for distribution in late 2005.
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.